Trodelvy has become an increasingly requested medicine among Indian oncology centres treating triple-negative breast cancer, a subtype known for its aggressive course and historically limited treatment options. As demand for this antibody-drug conjugate grows, hospital procurement teams and pharmacies are asking more practical questions — less about the science, which is well established in oncology literature, and more about how to source it reliably, verify authenticity, and manage the logistics involved in supplying a complex biologic medicine. This guide addresses those sourcing questions from a distributor’s perspective.
Topics
